| Cat.No.: | EAb-1027 |
| Product Name: | SIRT3 Polyclonal Antibody |
| Antibody Type: | Polyclonal |
| Conjugate: | Unconjugated |
| Host: | Rabbit |
| Isotype: | IgG |
| Purification: | Affinity Purified |
| Appearance: | Liquid |
| Formulation: | PBS with 0.02% sodium azide, 50% glycerol, pH7.3. |
| Applications: | IHC, WB |
| Recommended Dilutions/Conditions: |
WB, IHC; Recommended dilution: WB 1:500 - 1:2000, IHC 1:100 - 1:200 Recommended dilutions/conditions may not be available for all applications. Specific conditions for reactivity should be optimized by the end user. |
| Species Reactivity: | Human, Mouse |
| Storage: | -20°C |
| Warning: | For Research Use Only! Not For Use in Humans. |
| Alternative Name: | SIR2L3 |
| Scientific Background: | SIRT3 is a member of the sirtuin (silent mating type information regulation 2 homolog) family of proteins which are characterized by a sirtuin core domain and are grouped into 4 class types. Sirtuins share NAD dependency for their enzymatic activity, but some show NAD-dependent deacetylase activity, while others exhibit ADP ribosyltransferase activity or both. Sirtuins may act to influence a wide range of cellular processes such as aging, transcription, apoptosis, inflammation and stress resistance. Seven members make up the family of sirtuins in mammals (SirT1-T7). SIRT3 is a Class I sirtuin. |
| Product Types | ||
| ◆ Extracts & Lysates | ||
| EL-0016 | Recombinant Human SIRT1 Lysate | Inquiry |
| EL-0017 | Recombinant Human SIRT2 293 Cell Lysate | Inquiry |
| EL-0018 | Recombinant Human SIRT3 293 Cell Lysate | Inquiry |
| ◆ Synthetic Peptides | ||
| SP-0017 | Fluorogenic Sirtuin 5 Substrate | Inquiry |
| SP-0018 | Fluorogenic Sirtuin 6 Substrate | Inquiry |
| Related Gene / Proteins | |||
| Siah2 | SIK1 | SIMC1 | SIN3A |
| SIN3B | SIP1 | Sir2p | SIRT |
| SIRT1 | SIRT2 | SIRT3 | SIRT4 |
| SIRT5 | sirt6 | SIRT7 | SIX3 |
USA
Enter your email here to subscribe.
Follow us on
Easy access to products and services you need from our library via powerful searching tools
